Fig. 3
From: Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
A. Observed versus predicted cumulative incidence of new hypertension (HTN) rates at 1Â year, including population and Framingham risk-adjusted rate for ibrutinib [11, 24]. Reflects the JNC-8 HTN cutoff of 140/90Â mmHg, in comparison with established HTN prediction models.24 Subjects without known discussion of parenteal history of HTN were assigned a value of 1 (i.e., one of two parents with HTN) in the Framingham model B. Observed versus predicted cumulative incidence of new HTN, including incidence of grade 3 or higher HTN, at 0, 3, 6, 9, and 12Â months